ArticleAnnals of clinical and translational neurology2026

Reply to Letter: "Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring" by Saccà and Pelto Regarding "Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab".

Lea Gerischer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.